Saxagliptin/metformin immediate release

Drug Profile

Saxagliptin/metformin immediate release

Alternative Names: Kombiglyze; Komboglyze; Metformin immediate release/saxagliptin; Metformin IR/saxagliptin; Onglyza/metformin IR FDC; Saxagliptin/metformin IR

Latest Information Update: 14 Oct 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Adamantanes; Antihyperglycaemics; Biguanides; Dipeptides; Insulin sensitisers; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Feb 2014 AstraZeneca acquires saxagliptin/metformin immediate release from Bristol-Myers Squibb
  • 31 Dec 2013 Preregistration for Type-2 diabetes mellitus in China (PO)
  • 30 Jun 2013 Launched for Type-2 diabetes mellitus in European Union (PO) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top